Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine
pCR: hormone receptor‐positive · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer
Capecitabine‐containing regimens showed no clear difference in pCR: hormone receptor‐positive compared with non‐capecitabine‐containing regimens (moderate certainty).
1 finding from 1 review
- Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer 2021 · Cochrane Headline outcomes onlyOR 1.22 [0.76, 1.95]4 studies · 964 participantsModerate